Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma
Background:
This is the first clinical trial to investigate CPD in multiple myeloma.
- Results suggest that the regimen is a well-tolerated and highly active combination for patients with relapsed/refractory multiple myeloma.
Used by permission: Jatin J. Shah, MD, MD Anderson Cancer Center